# Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients

> **NCT06934967** · PHASE3 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 12 (estimated)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria (PNH)

## Interventions

- **DRUG:** LNP023

## Key facts

- **NCT ID:** NCT06934967
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-28
- **Primary completion:** 2031-11-19
- **Final completion:** 2031-12-19
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06934967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06934967, "Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06934967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*